Status:
TERMINATED
Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic Factors
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions:
Bladder Cancer
Eligibility:
All Genders
Brief Summary
To determine if there is an association between basic fibroblast growth factor,vascular endothelial growth factor, and interleukin levels and a patients response to BCG treatment ( as standard treatme...
Detailed Description
200 patients that are candidates for intravesical BCG therapy and 20 control patients with no history of malignancy will be enrolled. The study group wol;; be asked to provide a urine sample just prio...
Eligibility Criteria
Inclusion
- 200 study group 1. Must be a candidate for BCG therapy. 20 control group 1. No history of malignancy.
Exclusion
- N/A
Key Trial Info
Start Date :
October 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00216814
Start Date
October 1 2003
End Date
September 1 2007
Last Update
April 22 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
London Health Sciences Centre
London, Ontario, Canada, N6A 4G5